Overview

To Compare the Safety, Tolerability, and Pharmacokinetics of QBX258 in Patients With Asthma

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is designed to compare the safety, tolerability, and pharmacokinetics of QBX258 (sequential administration of a fixed dose of VAK694 and single ascending doses of QAX576) in patients with well-controlled mild to moderate asthma.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals